vs
Side-by-side financial comparison of Cricut, Inc. (CRCT) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Cricut, Inc. is the larger business by last-quarter revenue ($203.6M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 10.3%).
Cricut, Inc. is an American brand of cutting plotters, or computer-controlled cutting machines, designed for home crafters. The machines are used for cutting paper, felt, vinyl, fabric and other materials such as leather, matboard, and wood.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CRCT vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $203.6M | $168.4M |
| Net Profit | $7.8M | — |
| Gross Margin | 47.4% | — |
| Operating Margin | 6.8% | 50.6% |
| Net Margin | 3.8% | — |
| Revenue YoY | -2.7% | 143.7% |
| Net Profit YoY | -34.7% | — |
| EPS (diluted) | $0.03 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $203.6M | $168.4M | ||
| Q3 25 | $170.4M | $87.3M | ||
| Q2 25 | $172.1M | $82.4M | ||
| Q1 25 | $162.6M | $65.0M | ||
| Q4 24 | $209.3M | $69.1M | ||
| Q3 24 | $167.9M | $51.6M | ||
| Q2 24 | $167.9M | $73.8M | ||
| Q1 24 | $167.4M | $137.7M |
| Q4 25 | $7.8M | — | ||
| Q3 25 | $20.5M | $-31.3M | ||
| Q2 25 | $24.5M | $-12.7M | ||
| Q1 25 | $23.9M | $-40.5M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $11.5M | $-29.5M | ||
| Q2 24 | $19.8M | $-61.9M | ||
| Q1 24 | $19.6M | $61.0M |
| Q4 25 | 47.4% | — | ||
| Q3 25 | 55.2% | — | ||
| Q2 25 | 59.0% | — | ||
| Q1 25 | 60.5% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 46.1% | — | ||
| Q2 24 | 53.5% | — | ||
| Q1 24 | 54.7% | — |
| Q4 25 | 6.8% | 50.6% | ||
| Q3 25 | 13.3% | -11.4% | ||
| Q2 25 | 17.5% | 8.6% | ||
| Q1 25 | 18.0% | -34.0% | ||
| Q4 24 | 6.6% | -6.4% | ||
| Q3 24 | 6.3% | -31.0% | ||
| Q2 24 | 15.7% | 3.5% | ||
| Q1 24 | 15.1% | 52.5% |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 12.0% | -35.9% | ||
| Q2 25 | 14.2% | -15.4% | ||
| Q1 25 | 14.7% | -62.2% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 6.8% | -57.2% | ||
| Q2 24 | 11.8% | -83.9% | ||
| Q1 24 | 11.7% | 44.3% |
| Q4 25 | $0.03 | $0.32 | ||
| Q3 25 | $0.10 | $-0.16 | ||
| Q2 25 | $0.11 | $-0.06 | ||
| Q1 25 | $0.11 | $-0.21 | ||
| Q4 24 | $0.06 | $-0.14 | ||
| Q3 24 | $0.05 | $-0.15 | ||
| Q2 24 | $0.09 | $-0.33 | ||
| Q1 24 | $0.09 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.6M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $343.6M | $-302.0M |
| Total Assets | $580.8M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $275.6M | $167.9M | ||
| Q3 25 | $207.1M | $92.4M | ||
| Q2 25 | $376.9M | $86.1M | ||
| Q1 25 | $356.7M | $114.6M | ||
| Q4 24 | $336.9M | $144.8M | ||
| Q3 24 | $246.9M | $144.7M | ||
| Q2 24 | $299.5M | $189.3M | ||
| Q1 24 | $281.7M | $226.6M |
| Q4 25 | $343.6M | $-302.0M | ||
| Q3 25 | $358.4M | $-451.4M | ||
| Q2 25 | $308.9M | $-433.5M | ||
| Q1 25 | $490.2M | $-426.2M | ||
| Q4 24 | $466.8M | $-388.7M | ||
| Q3 24 | $475.8M | $-370.2M | ||
| Q2 24 | $448.5M | $-344.2M | ||
| Q1 24 | $552.6M | $-294.3M |
| Q4 25 | $580.8M | $465.9M | ||
| Q3 25 | $564.3M | $364.0M | ||
| Q2 25 | $721.5M | $347.1M | ||
| Q1 25 | $681.7M | $324.0M | ||
| Q4 24 | $693.0M | $343.8M | ||
| Q3 24 | $663.8M | $314.1M | ||
| Q2 24 | $742.1M | $352.3M | ||
| Q1 24 | $723.7M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 10.58× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $45.2M | ||
| Q3 25 | $20.5M | $-4.3M | ||
| Q2 25 | $36.2M | $-31.4M | ||
| Q1 25 | $61.2M | $-22.6M | ||
| Q4 24 | $103.1M | $-35.0M | ||
| Q3 24 | $70.2M | $-35.3M | ||
| Q2 24 | $35.0M | $-7.2M | ||
| Q1 24 | $56.7M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 10.58× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | 8.64× | — | ||
| Q3 24 | 6.11× | — | ||
| Q2 24 | 1.77× | — | ||
| Q1 24 | 2.89× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRCT
| Platform | $83.9M | 41% |
| Connected Machines | $65.2M | 32% |
| Accessories And Materials | $54.4M | 27% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
